OptiNose sniffs out $48.5m from Avista Capital | AltAssets Private Equity News

Subscribe today

Advanced
Search

OptiNose sniffs out $48.5m from Avista Capital

8 Jun 2010

Norwegian nasal drug delivery technology developer OptiNose has secured a $48.5m investment from US private equity firm Avista Capital.

Sorry, to read the full story you must be a Premium Subscriber

Are you a subscriber?

In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.

Become a Premium Subscriber
for only £150 / €180 / $225 p.a.

Login area

If you are already a AltAssets subscriber please log in below.